Loading
KT
Karuna Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HEALY JAMES, was filed 01 Jul 2022.
Karuna Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Karuna Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Boston. It was founded in 2009. Nothing new has been filed by managers of Karuna Therapeutics, Inc. in twelve months, the latest record being from 18 March 2024.
Since 2020, the database holds 4 purchases and 27 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
172
Thresholds
n/a
Buy Volume
€3M
4 ops. · all time
Sell Volume
€38M
27 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$563.1k
Net income-US$373.4M-66311.9% margin
Last declaration on 18 March 2024
Declarations172 total
990 shares@ US$330.0046.7% of flowCommon StockSEC:0001140361-24-013932:0
5,000 shares@ US$330.0058.2% of flowCommon StockSEC:0001140361-24-013927:0
13,977 shares@ US$330.0080.2% of flowCommon StockSEC:0001140361-24-013930:0
990 shares@ US$330.0024.8% of flowCommon StockSEC:0001140361-24-013931:0
32,500 shares@ US$330.0072.1% of flowCommon StockSEC:0001140361-24-013925:0
10,342 shares@ US$330.0055.9% of flowCommon StockSEC:0001140361-24-013928:0
36,117 shares@ US$330.0083.7% of flowCommon StockSEC:0001140361-24-013922:0
14,009 shares@ US$330.0098.1% of flowCommon StockSEC:0001140361-24-013923:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013924:0
990 shares@ US$330.0052.1% of flowCommon StockSEC:0001140361-24-013926:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013935:0
2,046 shares@ US$330.004.2% of flowCommon StockSEC:0001140361-24-013933:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013934:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-24-029406:0
47,378 shares@ US$315.1892.3% of flowCommon StockSEC:0000950170-24-024999:0
27,510 shares@ US$7.271.2% of flowCommon StockSEC:0000950170-24-020397:0
278 shares@ US$318.001.9% of flowCommon StockSEC:0000950170-24-015963:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-24-013959:0
1,011 shares@ US$317.145.6% of flowCommon StockSEC:0000950170-24-013962:0
804 shares@ US$317.141.6% of flowCommon StockSEC:0000950170-24-013963:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-24-003372:0
8,694 shares@ US$316.3044.1% of flowCommon StockSEC:0000950170-23-073877:0
3,828 shares@ US$316.3041.8% of flowCommon StockSEC:0000950170-23-073878:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-23-069766:0
2,500 shares@ US$5.450.1% of flowCommon StockSEC:0000950170-23-063121:0
25 of 172 declarations
About Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. (ticker KRTX) was a U.S.-based biopharmaceutical company focused on neuroscience and psychiatry. It was listed on the NASDAQ in the United States, and it ceased to operate as a standalone public company after Bristol Myers Squibb completed its acquisition on March 18, 2024. As a result, Karuna is best understood today as a former listed biotech whose legacy centered on the development of differentiated therapies for psychiatric and neurological disorders. Its historic headquarters were in Boston, Massachusetts, at 99 High Street. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1771917/000114036124013927/xslF345X05/form4.xml?utm_source=openai))
Karuna was built around a research platform targeting central nervous system diseases, with a particular emphasis on muscarinic receptor modulation. Its lead asset was KarXT (xanomeline-trospium), an oral, first-in-class or potentially first-in-class antipsychotic program designed for adult schizophrenia, with additional development work in Alzheimer’s disease psychosis and other neuropsychiatric settings. The company’s story was that of a focused clinical-stage innovator rather than a diversified pharmaceutical group: it aimed to create value through a single highly differentiated scientific platform and a small number of high-impact programs. ([nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai))
Read moreShow less
From a competitive standpoint, Karuna occupied a niche at the intersection of psychiatry and neurology, competing indirectly against established antipsychotics and against the broader industry’s search for more effective treatments with improved tolerability. Its competitive edge lay in KarXT’s novel mechanism and the possibility of addressing unmet needs in schizophrenia and related disorders. At the same time, Karuna had the classic risk profile of a clinical-stage biotech: heavy dependence on one lead asset, binary regulatory milestones, and no large-scale commercial franchise to cushion setbacks. ([nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai))
Geographically, Karuna’s business was overwhelmingly U.S.-centered, with its research and corporate base in Boston and its initial commercial/regulatory ambition focused on the U.S. market through the FDA. A major recent milestone was the December 22, 2023 announcement that Bristol Myers Squibb would acquire Karuna for $330.00 per share in cash, implying an equity value of about $14.0 billion. The deal closed on March 18, 2024, and Karuna became part of Bristol Myers Squibb’s neuroscience portfolio. For international investors, this means KRTX is now primarily a historical reference point in the U.S. biotech sector rather than an independently traded operating company. ([nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai))
